Latest Dilution News

Page 18 of 323
First Lithium has secured three-year renewals for its Gouna and Faraba exploration licences in Mali, removing the stated hold-up to its maiden JORC resource. The company now faces a more familiar challenge: funding the next phase while seeking ASX re-admission.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Northstone Resources has entered voluntary suspension while it finalises a proposed capital raising, with an announcement expected by 5 November 2026. The size, pricing, structure and potential dilution remain undisclosed.
Victor Sage
Victor Sage
4 Nov 2026
Arbitr Group has proposed a A$4.86 million capital raising to fund an organisational reset and push into enterprise AI, while warning that non-participating shareholders could face about 43% dilution. The plan also targets A$2 million in recurring annual cost savings and a calendar 2026 release for its Enterprise AI Context Engine.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Felix Gold has secured $7.25 million in placement commitments at a 14.3% discount and will seek a further $1 million from eligible shareholders. The funds will support mine permitting, refinery studies, drilling and resource work, but part of the raise still requires shareholder approval.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Titan Minerals has been suspended from trading while it finalises funding arrangements, with the company expecting to make a market announcement by 9 November. The suspension leaves the size, structure and potential impact of the funding undisclosed for now.
Maxwell Dee
Maxwell Dee
4 Nov 2026
PMET Resources has increased contained caesium oxide at its Shaakichiuwaanaan project by 55% and added maiden rubidium and CV4 lithium resources. The update is designed to feed an updated feasibility study and broader economic assessment due before year end, but the new resources are not yet reserves.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Cynata Therapeutics has completed its $912,962 entitlement offer and secured firm commitments for a further $550,000 placement. The second raise still requires shareholder approval and will bring additional shares and options into an already heavily funded capital structure.
Ada Torres
Ada Torres
4 Nov 2026
Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.
Victor Sage
Victor Sage
4 Nov 2026
Mosaic has swung to a third-quarter loss as production curtailments, weak volumes and sharply higher sulfur costs overwhelmed stronger fertiliser prices. The company is cutting capital spending, extending debt maturities and betting that cheaper sulfur will begin to help in early 2027.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Supermicro’s preliminary fiscal first-quarter sales nearly quadrupled year on year to US$19.9 billion, as net income reached US$1.59 billion. The company forecast fiscal 2027 revenue of US$72 billion to US$82 billion, although weaker sequential margins and negative operating cash flow add important qualifications.
Sophie Babbage
Sophie Babbage
4 Nov 2026
Jack Henry delivered a stronger-than-expected fiscal first quarter, with revenue, operating income and earnings per share all accelerating year on year. Cloud, card, digital and faster-payments demand supported the result, while buybacks and higher borrowings shaped the capital picture.
Sophie Babbage
Sophie Babbage
4 Nov 2026
American International Group delivered a sharp rise in reported third-quarter profit, supported by investment gains and higher insurance premiums. But adjusted earnings fell as catastrophe losses increased and underwriting income weakened, creating a more mixed picture beneath the headline result.
Victor Sage
Victor Sage
4 Nov 2026

Browse the archive

Full archive